secwatch.observer — SEC 8-K summary
======================================

Issuer:     Akebia Therapeutics, Inc. (AKBA)
CIK:        0001517022
Form:       8-K
Filed at:   2026-04-01T23:59:59+00:00
Accession:  0001517022-26-000024
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Akebia appoints Philip Vickers to board, replacing retiring Steven Gilman
-------------------------------------------------------------------------

- Steven Gilman resigned as Class I director effective April 1, 2026; retirement not due to any disagreement.
- Philip Vickers elected Class I director effective April 1, 2026; term expires at 2027 annual meeting.
- Vickers appointed to Compensation and R&D Committees; receives standard non-employee director compensation.
- Vickers granted 214,400 options at $1.41/share on April 1, plus annual cash retainers of $50,000.
- Vickers is CEO of Solu Therapeutics; over 30 years biopharma leadership including Shire and Pfizer.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1517022/000151702226000024/0001517022-26-000024-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1517022/000151702226000024/akba-20260327.htm
  HTML page:      https://secwatch.observer/filing/0001517022-26-000024

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer